É. Sbidian

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury et al. · Scientific Reports · 2022 · 171 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France

T.A. Duong, É. Sbidian, L. Valeyrie‐Allanore et al. · Orphanet Journal of Rare Diseases · 2011 · 137 citations · Full text

Medicine, Internal Medicine, Neurology +15

Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis

C. Phan, Mathilde Touvier, Emmanuelle Kesse‐Guyot et al. · JAMA Dermatology · 2018 · 126 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +10

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira et al. · Annals of the Rheumatic Diseases · 2022 · 118 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Antihypertensive Drugs and COVID-19 Risk

Laura Semenzato, Jérémie Botton, Jérôme Drouin et al. · Hypertension · 2021 · 117 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17